Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bellicum Pharmaceuticals (BLCM) stock

Learn how to easily invest in Bellicum Pharmaceuticals stock.

Bellicum Pharmaceuticals, Inc
+$0.06 (+2.10%)

Bellicum Pharmaceuticals, Inc is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the NASDAQ and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 10 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Bellicum Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BLCM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bellicum Pharmaceuticals stock price (NASDAQ: BLCM)

Use our graph to track the performance of BLCM stocks over time.

Bellicum Pharmaceuticals shares at a glance

Information last updated 2021-07-22.
Latest market close$2.98
52-week range$2.57 - $8.00
50-day moving average $3.22
200-day moving average $3.71
Wall St. target price$4.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.31

Buy Bellicum Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bellicum Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bellicum Pharmaceuticals price performance over time

Historical closes compared with the close of $2.98 from 2021-05-28

1 week (2021-07-17) N/A
1 month (2021-06-28) -18.58%
3 months (2021-04-28) -15.58%
6 months (2021-01-24) N/A
1 year (2020-07-24) N/A
2 years (2019-07-24) N/A
3 years (2018-07-24) N/A
5 years (2016-07-24) N/A

Bellicum Pharmaceuticals financials

Revenue TTM $500,000
Gross profit TTM $-38,552,000
Return on assets TTM -46.44%
Return on equity TTM -378.68%
Profit margin 0%
Book value $0.25
Market capitalisation $25.1 million

TTM: trailing 12 months

Shorting Bellicum Pharmaceuticals shares

There are currently 1.0 million Bellicum Pharmaceuticals shares held short by investors – that's known as Bellicum Pharmaceuticals's "short interest". This figure is 3.1% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Bellicum Pharmaceuticals shares can be evaluated.

Bellicum Pharmaceuticals's "short interest ratio" (SIR)

Bellicum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Bellicum Pharmaceuticals shares currently shorted divided by the average quantity of Bellicum Pharmaceuticals shares traded daily (recently around 155886.03945372). Bellicum Pharmaceuticals's SIR currently stands at 6.59. In other words for every 100,000 Bellicum Pharmaceuticals shares traded daily on the market, roughly 6590 shares are currently held short.

However Bellicum Pharmaceuticals's short interest can also be evaluated against the total number of Bellicum Pharmaceuticals shares, or, against the total number of tradable Bellicum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellicum Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Bellicum Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1387% of the tradable shares (for every 100,000 tradable Bellicum Pharmaceuticals shares, roughly 139 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Bellicum Pharmaceuticals.

Find out more about how you can short Bellicum Pharmaceuticals stock.

Bellicum Pharmaceuticals share dividends

We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.

Have Bellicum Pharmaceuticals's shares ever split?

Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 5 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.

Bellicum Pharmaceuticals share price volatility

Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $2.574 up to $8. A popular way to gauge a stock's volatility is its "beta".

BLCM.US volatility(beta: 1.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellicum Pharmaceuticals's is 1.7737. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bellicum Pharmaceuticals overview

Bellicum Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc. ; BioVec Pharma, Inc. ; ARIAD Pharmaceuticals, Inc.

Stocks similar to Bellicum Pharmaceuticals

Frequently asked questions

What percentage of Bellicum Pharmaceuticals is owned by insiders or institutions?
Currently 0.587% of Bellicum Pharmaceuticals shares are held by insiders and 21.571% by institutions.
How many people work for Bellicum Pharmaceuticals?
Latest data suggests 10 work at Bellicum Pharmaceuticals.
When does the fiscal year end for Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals's fiscal year ends in December.
Where is Bellicum Pharmaceuticals based?
Bellicum Pharmaceuticals's address is: 3730 Kirby Drive, Houston, TX, United States, 77098
What is Bellicum Pharmaceuticals's ISIN number?
Bellicum Pharmaceuticals's international securities identification number is: US0794814048
What is Bellicum Pharmaceuticals's CUSIP number?
Bellicum Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 079481107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site